Safety and immunogenicity of SpikoGen®, an Advax-CpG55.2-adjuvanted SARS-CoV-2 spike protein vaccine: a phase 2 randomized placebo-controlled trial in both seropositive and seronegative populations

OBJECTIVE: We aimed to investigate the immunogenicity and safety of SpikoGen®, a subunit COVID-19 vaccine composed of a recombinant prefusion-stabilized SARS-CoV-2 spike protein combined with the Advax-CpG55.2™ adjuvant, in seronegative and seropositive populations as primary vaccination. METHODS: T...

Descripción completa

Detalles Bibliográficos
Autores principales: Tabarsi, Payam, Anjidani, Nassim, Shahpari, Ramin, Mardani, Masoud, Sabzvari, Araz, Yazdani, Babak, Roshanzamir, Khashayar, Bayatani, Behnam, Taheri, Ali, Petrovsky, Nikolai, Li, Lei, Barati, Saghar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9012510/
https://www.ncbi.nlm.nih.gov/pubmed/35436611
http://dx.doi.org/10.1016/j.cmi.2022.04.004

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9012510/
https://www.ncbi.nlm.nih.gov/pubmed/35436611
http://dx.doi.org/10.1016/j.cmi.2022.04.004

Ejemplares similares